The World Health Organization currently estimates
that there may be 50 million dengue infections worldwide
every year. To date, there is no effective vaccine or antiviral
drug available against these dengue diseases [1,2]. Thus, to overcome
this or any other future DV endemics, a detailed understanding
at the molecular level of DV replication and inhibition is crucial,
particularly for the design of novel dengue antivirus inhibitors.